DailyIQ
|
Sector:HealthcareAll sectors
Last updated 4 minutes ago

COR·Cencora, Inc.

$.
+. (+.%)
After Hours
High
$304.79
Open
$301.52
Market Cap
59.19B
52W High
$377.54
Low
$300.76
P. Close
$303.60
P/E
23.22
52W Low
$244.82
Fwd P/E
15.32
DailyIQ Est.
$364.93
Technical Score (1D)
55
BUY
News Sentiment
57
BULLISH
Evercore ISI’s recent upgrade of Cencora’s price target to $330 from $300 signals a bullish reassessment driven by the company’s stronger earnings guidance and its solid competitive position in the specialty‑chemicals space, which could lift short‑term sentiment and attract new buyers. The upgrade also raises expectations for near‑term profitability, so traders should watch the upcoming earnings release for confirmation of the guidance. Cencora has scheduled its third‑quarter fiscal 2026 earnings announcement for Wednesday, August 5, 2026, with a conference call at 8:30 a.m. ET, offering an early window into revenue, margin, and product‑pipeline updates that will be critical for the next 1–10 trading days. A DCF analysis that flags the stock as undervalued, with projected free‑cash‑flow growth exceeding current market pricing, reinforces the case for the higher target and suggests that the market may still be underpricing future cash flows. However, Argus Research’s drastic cut of the target to $340 from $4,000—while maintaining a buy rating—highlights lingering valuation concerns and underscores the importance of cost‑control initiatives and earnings performance. B of A Securities and BofA have both nudged their targets upward to $285, reflecting modest confidence in the company’s near‑term prospects and a more favorable view of its pipeline, which aligns with the broader consensus of overweight. The convergence of these analyst views points to a range of expectations that will be tested at the earnings call, so traders should monitor the call’s guidance, any regulatory updates that could impact product pipelines, and the company’s cost‑control progress. In the next 1–10 trading days, the market will likely react to the earnings guidance and any surprises in revenue or margin, so staying alert to the conference call’s details and subsequent analyst commentary will be key.
Earnings Summary
Cencora, Inc. (COR) operates as a global pharmaceutical distribution and services company, sourcing and distributing generics, injectables, OTC and specialty pharmaceuticals while offering pharmacy management, consulting and data analytics to hospitals, pharmacies and clinics. The company’s dual U.S. and International Healthcare Solutions segments place it firmly within the medical distribution sector of the broader healthcare industry. In the most recent fiscal quarters, Cencora reported earnings that consistently beat consensus estimates: Q4 2024 EPS of $3.73 versus an estimate of $3.52 and revenue of $81.49 billion; Q1 2025 EPS of $4.42 versus $4.10 and revenue of $75.45 billion; Q2 2025 EPS of $4.00 versus $3.84 and revenue of $80.66 billion; Q3 2025 EPS of $3.84 versus $3.79 and revenue of $83.73 billion. While EPS showed a modest decline from $4.42 in Q1 2025 to $3.84 in Q3 2025, revenue grew from $75.45 billion to $83.73 billion, indicating accelerating top‑line momentum. The company has maintained a streak of earnings beats in four consecutive quarters, underscoring a pattern of outperforming analyst expectations even as earnings per share fluctuated. Historically, Cencora’s revenue has risen year‑over‑year in each quarter, and the firm has consistently delivered EPS beats, suggesting disciplined cost management and a robust distribution network. Recent analyst commentary highlights a bullish reassessment: Evercore ISI lifted its price target to $330 from $300, citing stronger earnings guidance and a solid competitive position in specialty chemicals, while BofA and BofA Securities modestly raised targets to $285, reflecting confidence in near‑term prospects. Investors should watch the upcoming Q3 FY2026 earnings call for guidance on revenue growth, margin expansion, and any updates on cost‑control initiatives, as well as regulatory developments that could impact the pharmaceutical distribution landscape.

EPS

EstBeatMiss
$3.34$3.74$4.14$4.53$4.93Q4'24Q1'25Q2'25Q3'25Q2'26Q3'26
QtrEstActual+/−
Q3'26$4.34 - -
Q2'26$4.33$4.75+9.6%
Q3'25$3.79$3.84+1.4%
Q2'25$3.84$4.00+4.2%
Q1'25$4.10$4.42+7.9%
Q4'24$3.52$3.73+6.0%

Revenue

EstBeatMiss
$73.7B$77.5B$81.3B$85.2B$89.0BQ4'24Q1'25Q2'25Q3'25Q2'26Q3'26
QtrEstActual+/−
Q3'26$84.2B - -
Q2'26$87.2B$78.4B-10.2%
Q3'25 - $83.7B -
Q2'25 - $80.7B -
Q1'25 - $75.5B -
Q4'24 - $81.5B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

COR Stock Snapshot

COR is currently trading at $303.44, giving Cencora, Inc. a market cap of 59.19B and a P/E ratio of 23.2. Today's range spans $300.76–$304.79, with shares opening at $301.52 and moving down $0.16 (0.1%) from the prior close. DailyIQ's technical score sits at 55/100 (HOLD) with a news sentiment reading of 57/100.

Over the past year COR has traded between $244.82 and $377.54 - the current price is +23.9% off the 52-week low and -19.6% from the high. 22 analysts cover the stock with a Buy consensus and a mean 12-month target of $353.50 (range $285.00–$412.00), implying upside of +16.5%.

It's a pause for COR: technical score 55/100 (HOLD), sentiment neutral (57/100), price $303.44 (in the middle of its 52-week range). (P/E: 23.2) At 59.19B in Healthcare market cap, pauses like this often occur when the stock has run ahead of near-term fundamental catalysts and is waiting for earnings or macro data to validate the prior move. Annual range: $244.82–$377.54. The consolidation is the story for now.

In neutral phases, large-cap Healthcare names like COR are often where sector rotation debates play out quietly — at 59.19B in capitalization, the stock receives incremental allocation from funds reducing mega-cap exposure without the volatility of a small-cap entry. The 55/100 (HOLD) and neutral sentiment (57/100) at $303.44 (in the middle of its 52-week range) describe a stock that is being considered rather than avoided.